All patients have completed treatment in the Phase 1 trial of Oxford Vacmedix’s lead cancer vaccine OVM-200

Oxford, UK – 17 November 2025

Press Release – Last patient out milestone for OVM-200

Oxford Vacmedix (OVM) announced today the last patient out milestone in the Phase 1 trial of lead cancer vaccine OVM-200. Phase 1b, the second part of the trial, has involved patients being treated with up to six months therapy of OVM-200, at four leading hospitals in the UK. The extended dosing protocol was first suggested by the clinical investigators in the trial following the excellent safety record in Phase 1a. OVM-200 is a novel form of immunotherapy developed using OVM’s recombinant overlapping peptide (ROP) platform. It targets survivin, a protein overexpressed by cancer cells, which prevents them being attacked by the body’s immune system. This trial is both the first time OVM-200 has been used in people and also the first time any ROP based vaccine has been tested in the clinic.

The trial has focused on establishing the initial safety profile and examining the immune response in patients with three tumour types – non small cell lung cancer (NSCLC), prostate cancer and ovarian cancer. 36 patients have participated in this Phase 1 trial with the most recent NSCLC patient doing particularly well and receiving the maximum allowed 11 immunisations over six months without disease progression. The database for the trial will be locked over the next four weeks when all patient data has been logged. The first part of the trial, Phase 1a, showed both excellent safety and a strong immune response. Phase 1b is anticipated to confirm and enhance these results for the vaccine.

William Finch, CEO of Oxford Vacmedix, said:

We are delighted to reach this important milestone, which would not have been possible without the doctors and nurses at the trial centres and of course the patients who have participated. We expect to have the final clinical trial report very soon and are very pleased to be seeing safety, immunogenicity and, most excitingly, some initial signs of clinical activity.

Dr Tom Morris, Chief Medical Officer of Oxford Vacmedix added:

This ROP technology has been developed from an initial concept in the laboratory and has now been tested as a treatment for patients with advanced cancers that have exhausted all other therapies. The vaccination approach both stimulates the body’s immune system to attack the cancer and has the potential to enhance the efficacy of other immune oncology agents. Completing this Phase I trial is a critical first step towards having effective cancer vaccines.

ENDS

For more information or to inquire about investing in Series B please contact:

William Finch, CEO, Oxford Vacmedix

T: +44 (0)1865 742087 | M: +44(0)7769 903711 | E: wfinch@oxfordvacmedix.com

Dr Nam Park, Chief Business Officer, Oxford Vacmedix

T: +44 (0)1865 742087 | M: +44(0)7904 613938 | E: npark@oxfordvacmedix.com

Notes to Editor

About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a bio-pharma company that was spun out from the University of Oxford’s Department of Oncology and is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Professor Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for therapeutic vaccines and diagnostics in cancer and infectious diseases.

The technology uses the novel, proprietary platform of ROPs to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and in infectious diseases.

OVM is developing two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at head and neck and cervical cancer, and OVM-200 represents a new type of immunotherapy utilising survivin to target solid tumours. Both vaccines will be tested as single agents and in combination with IO agents.

OVM has recently secured the lead investment in Series B from Dx&Vx, a leading South Korean Pharma company, listed on KOSDAQ, and from existing shareholders in China. The company is currently seeking further Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and also in combination.

For more information: https://www.oxfordvacmedix.com